Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Sechter

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
L'Encephale|April 17, 1999
[Grapefruit juice as a contraindication? An approach in psychiatry]P Vandel, W Regina, I Reix, et al.
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
Advances in Biochemical Psychopharmacology|January 1, 1984
3H-imipramine and 3H-desipramine binding sites in depressionS Z Langer, R Raisman, D Sechter, et al.
Psychopharmacology|January 1, 1982
3H-imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteersR Raisman, M S Briley, F Bouchami, et al.
L'Encephale|July 6, 2013
[Sexual dysfunction and depression: Validity of a French version of the ASEX scale]M Briki, E Haffen, J Monnin, et al.
Therapie|September 1, 2000
Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?P Vandel, E Haffen, S Vandel, et al.
Clinical Neuropharmacology|January 1, 1992
Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal resultsS Bouquet, S Vandel, G Bertschy, et al.
Human Psychopharmacology|December 1, 2004
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetineP Vandel, D Sechter, E Weiller, et al.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Journal of Receptor Research|January 1, 1987
Association of [3H]-imipramine and [3H]-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depressionS Z Langer, A M Galzin, M F Poirier, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
L'Encephale|April 17, 1999
[Grapefruit juice as a contraindication? An approach in psychiatry]P Vandel, W Regina, I Reix, et al.
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
Advances in Biochemical Psychopharmacology|January 1, 1984
3H-imipramine and 3H-desipramine binding sites in depressionS Z Langer, R Raisman, D Sechter, et al.
Psychopharmacology|January 1, 1982
3H-imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteersR Raisman, M S Briley, F Bouchami, et al.
L'Encephale|July 6, 2013
[Sexual dysfunction and depression: Validity of a French version of the ASEX scale]M Briki, E Haffen, J Monnin, et al.
Therapie|September 1, 2000
Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?P Vandel, E Haffen, S Vandel, et al.
Clinical Neuropharmacology|January 1, 1992
Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal resultsS Bouquet, S Vandel, G Bertschy, et al.
Human Psychopharmacology|December 1, 2004
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetineP Vandel, D Sechter, E Weiller, et al.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Journal of Receptor Research|January 1, 1987
Association of [3H]-imipramine and [3H]-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depressionS Z Langer, A M Galzin, M F Poirier, et al.
Pageof 9